Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.

Article Details

Citation
Copy to clipboard

Popowycz F, Fournet G, Schneider C, Bettayeb K, Ferandin Y, Lamigeon C, Tirado OM, Mateo-Lozano S, Notario V, Colas P, Bernard P, Meijer L, Joseph B

Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.

J Med Chem. 2009 Feb 12;52(3):655-63. doi: 10.1021/jm801340z.

PubMed ID
19128055 [ View in PubMed
]
Abstract

Pharmacological inhibitors of cyclin-dependent kinases (CDKs) have a wide therapeutic potential. Among the CDK inhibitors currently under clinical trials, the 2,6,9-trisubstituted purine (R)-roscovitine displays rather high selectivity, low toxicity, and promising antitumor activity. In an effort to improve this structure, we synthesized several bioisosteres of roscovitine. Surprisingly, one of them, pyrazolo[1,5-a]-1,3,5-triazine 7a (N-&-N1, GP0210), displayed significantly higher potency, compared to (R)-roscovitine and imidazo[2,1-f]-1,2,4-triazine 13 (N-&-N2, GP0212), at inhibiting various CDKs and at inducing cell death in a wide variety of human tumor cell lines. This approach may thus provide second generation analogues with enhanced biomedical potential.

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
(2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-olCyclin-dependent kinase 2IC 50 (nM)407.530Details
SeliciclibCyclin-dependent kinase 2IC 50 (nM)2207.530Details
SeliciclibCyclin-dependent kinase 7IC 50 (nM)8007.530Details
SeliciclibCyclin-dependent kinase 9IC 50 (nM)2307.530Details